NASDAQ: CHRNChronoscale Corp Stock
$13.66+0.44 (+3.33%)
Updated May 6, 2026
CHRN Price
$13.66
Fair Value Price
N/A
Market Cap
$48.68M
52 Week Low
$2.73
52 Week High
$15.33
P/E
-2.54x
P/B
23.29x
P/S
3.28x
PEG
N/A
Dividend Yield
N/A
Revenue
$11.57M
Earnings
-$15.69M
Gross Margin
52.9%
Operating Margin
-132.36%
Profit Margin
-135.7%
Debt to Equity
6.66
Operating Cash Flow
-$12M
Beta
0.82
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CHRN Overview
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CHRN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Industrial Machinery
Industry Rating
B
CHRN
Ranked#58 of 70
Ranked#58 of 70
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $30.24 | A | |
| $77.74 | A | |
| $69.81 | A |
Be the first to know about important CHRN news, forecast changes, insider trades & much more!
CHRN News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CHRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CHRN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CHRN is poor value based on its book value relative to its share price (23.29x), compared to the US Specialty Industrial Machinery industry average (5.77x)
P/B vs Industry Valuation
CHRN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CHRN due diligence checks available for Premium users.
Valuation
CHRN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.54x
Industry
-0.81x
Market
20.8x
CHRN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
23.29x
Industry
5.77x
CHRN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CHRN's financial health
Profit margin
Revenue
$2.1M
Net Income
-$6.9M
Profit Margin
-321.6%
CHRN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CHRN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$19.7M
Liabilities
$13.9M
Debt to equity
6.66
CHRN's short-term assets ($14.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHRN's short-term assets ($14.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHRN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CHRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
$0.0
Financing
$5.0M
CHRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CHRN vs Specialty Industrial Machinery Stocks
Chronoscale Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.